LumiThera_FDA
November 5, 2024

FDA Approves Lumithera’s Photobiomodulation Device for Dry AMD

Lumithera’s Valeda becomes the first FDA-approved treatment for vision loss caused by dry AMD Dry AMD sufferers in the United…

Espansione Group’s eye light_V2 02
June 3, 2024

Espansione Group’s eye-light® Expands Its Horizons: New CE (MDR) Mark for Corneal and Retinal Care

Espansione Group (Zona Artigianale Funo BO, Italy), a leader in medtech innovation in ophthalmology, announced today a major milestone for…

popular posts
Thiết kế chưa có tên (15)
May 13, 2025

Aflibercept 8mg Has Been Available for Over a Year. Here’s What nAMD Experts Are Saying About Early Experiences. 

latest posts
Dream OCT
May 16, 2025

Intalight’s DREAM OCT Platform Cleared for EU Market with CE Mark

The Potential for Better and Faster Drying with Longer Treatment Intervals Experts share how aflibercept 8 mg could reshape clinical practice (1)
May 13, 2025

The Potential for Better and Faster Drying with Longer Treatment Intervals

Thiết kế chưa có tên (15)
May 13, 2025

Aflibercept 8mg Has Been Available for Over a Year. Here’s What nAMD Experts Are Saying About Early Experiences. 

FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks
April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

MST Partners with Mani to Distribute Ophthalmic Surgical Blade Portfolio
April 18, 2025

MST Partners with MANI to Distribute Its Ophthalmic Surgical Blade Portfolio in the U.S.

Eylea HD for Macular Edema Following RVO
April 18, 2025

FDA Grants Priority Review to Eylea HD for Macular Edema Following RVO 

unnamed (22)
April 16, 2025

FDA Grants RMAT Designation to Atsena Therapeutics’ Gene Therapy for X-linked Retinoschisis

Apr11_Article
April 11, 2025

NexThera, Oculis and Bayer Report Advances in Retinal Disease Therapies

Discover our fascinating content at issuu

explore